Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725

Citigroup analyst Eric Joseph has initiated coverage on Madrigal Pharmaceuticals (NASDAQ: MDGL) with a Buy rating. The firm has set a price target of $725 for the stock.